Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry

I. García-Bolao, RS. Gardner, D. Gras, A. D'Onofrio, G. Mark, D. Nair, N. Lellouche, M. Novak, R. Lo, E. Chew, D. Wright, A. Kaplan, M. Bertini, S. Veraghtert, MM. Harbin, E. Matznick, P. Yong, KM. Stein

. 2025 ; 12 (3) : 1832-1847. [pub] 20241226

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015580

AIMS: Cardiac resynchronization therapy (CRT) is guideline recommended for the treatment of symptomatic heart failure (HF) with reduced left ventricular ejection fraction and prolonged QRS. However, patients with common comorbidities, such as persistent/permanent atrial fibrillation (AF), are often under-represented in clinical trials. METHODS: The Strategic Management to Optimize Response to Cardiac Resynchronization Therapy (SMART) registry (NCT03075215) was a global, multicentre, registry that enrolled de novo CRT implants, or upgrade from pacemaker or implantable cardioverter defibrillator to CRT-defibrillator (CRT-D), using a quadripolar left ventricular lead in real-world clinical practice. The primary endpoint was CRT response between baseline and 12 month follow-up defined as a clinical composite score (CCS) consisting of all-cause mortality, HF-associated hospitalization, New York Heart Association (NYHA) class and quality of life global assessment. RESULTS: The registry enrolled 2035 patients, of which 1558 had completed CCS outcomes at 12 months. The patient cohort was 33.0% female, mean age at enrolment was 67.5 ± 10.4 years and the mean left ventricular ejection fraction was 29.6 ± 7.9%. Notably, there was a high prevalence of mildly symptomatic patients (NYHA class I/II 51.3%), non-left bundle branch block (LBBB) morphology (38.0%), AF (37.2%) and diabetes mellitus (34.7%) at baseline. CCS at 12 months improved in 58.9% (n = 917) of patients; 20.1% (n = 313) of patients stabilized and 21.0% (n = 328) worsened. Several patient characteristics were associated with a lower likelihood of response to CRT including older age, ischaemic aetiology, renal dysfunction, AF, non-LBBB morphology and diabetes. Higher HF hospitalization (P < 0.001) and all-cause mortality (P < 0.001) were observed in patients with AF. These patients also had lower percentages of ventricular pacing than patients in sinus rhythm at baseline and follow-up (P < 0.001, both). A further association between AF and non-LBBB was observed with 81.4% of AF non-LBBB patients experiencing an HF hospitalization compared with 92.5% of non-AF LBBB patients (P < 0.001). Mortality between subgroups was also statistically significant (P = 0.019). CONCLUSIONS: This large, global registry enrolled a CRT-D population with higher incidence of comorbidities that have been historically underrepresented in clinical trials and provides new insight into factors influencing response to CRT. As defined by CCS, 58.9% of patients improved and 20.1% stabilized. Patients with AF had particularly worse clinical outcomes, higher HF hospitalization and mortality rates and lower percentages of ventricular pacing. High incidence of HF hospitalization in patients with AF and non-LBBB in this real-world cohort suggests that ablation may play an important role in increasing future CRT response rates.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015580
003      
CZ-PrNML
005      
20250731091108.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.15190 $2 doi
035    __
$a (PubMed)39722592
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a García-Bolao, Ignacio $u Department of Cardiology and Cardiac Surgery, Arrhythmia Unit, Navarra Institute for Health Research, Clinica Universidad de Navarra, Pamplona, Spain
245    10
$a Real-world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry / $c I. García-Bolao, RS. Gardner, D. Gras, A. D'Onofrio, G. Mark, D. Nair, N. Lellouche, M. Novak, R. Lo, E. Chew, D. Wright, A. Kaplan, M. Bertini, S. Veraghtert, MM. Harbin, E. Matznick, P. Yong, KM. Stein
520    9_
$a AIMS: Cardiac resynchronization therapy (CRT) is guideline recommended for the treatment of symptomatic heart failure (HF) with reduced left ventricular ejection fraction and prolonged QRS. However, patients with common comorbidities, such as persistent/permanent atrial fibrillation (AF), are often under-represented in clinical trials. METHODS: The Strategic Management to Optimize Response to Cardiac Resynchronization Therapy (SMART) registry (NCT03075215) was a global, multicentre, registry that enrolled de novo CRT implants, or upgrade from pacemaker or implantable cardioverter defibrillator to CRT-defibrillator (CRT-D), using a quadripolar left ventricular lead in real-world clinical practice. The primary endpoint was CRT response between baseline and 12 month follow-up defined as a clinical composite score (CCS) consisting of all-cause mortality, HF-associated hospitalization, New York Heart Association (NYHA) class and quality of life global assessment. RESULTS: The registry enrolled 2035 patients, of which 1558 had completed CCS outcomes at 12 months. The patient cohort was 33.0% female, mean age at enrolment was 67.5 ± 10.4 years and the mean left ventricular ejection fraction was 29.6 ± 7.9%. Notably, there was a high prevalence of mildly symptomatic patients (NYHA class I/II 51.3%), non-left bundle branch block (LBBB) morphology (38.0%), AF (37.2%) and diabetes mellitus (34.7%) at baseline. CCS at 12 months improved in 58.9% (n = 917) of patients; 20.1% (n = 313) of patients stabilized and 21.0% (n = 328) worsened. Several patient characteristics were associated with a lower likelihood of response to CRT including older age, ischaemic aetiology, renal dysfunction, AF, non-LBBB morphology and diabetes. Higher HF hospitalization (P < 0.001) and all-cause mortality (P < 0.001) were observed in patients with AF. These patients also had lower percentages of ventricular pacing than patients in sinus rhythm at baseline and follow-up (P < 0.001, both). A further association between AF and non-LBBB was observed with 81.4% of AF non-LBBB patients experiencing an HF hospitalization compared with 92.5% of non-AF LBBB patients (P < 0.001). Mortality between subgroups was also statistically significant (P = 0.019). CONCLUSIONS: This large, global registry enrolled a CRT-D population with higher incidence of comorbidities that have been historically underrepresented in clinical trials and provides new insight into factors influencing response to CRT. As defined by CCS, 58.9% of patients improved and 20.1% stabilized. Patients with AF had particularly worse clinical outcomes, higher HF hospitalization and mortality rates and lower percentages of ventricular pacing. High incidence of HF hospitalization in patients with AF and non-LBBB in this real-world cohort suggests that ablation may play an important role in increasing future CRT response rates.
650    _2
$a lidé $7 D006801
650    12
$a registrace $7 D012042
650    12
$a srdeční resynchronizační terapie $x metody $7 D058406
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a srdeční selhání $x terapie $x patofyziologie $x mortalita $7 D006333
650    _2
$a senioři $7 D000368
650    12
$a tepový objem $x fyziologie $7 D013318
650    _2
$a výsledek terapie $7 D016896
650    _2
$a následné studie $7 D005500
650    12
$a kvalita života $7 D011788
650    12
$a funkce levé komory srdeční $x fyziologie $7 D016277
650    _2
$a lidé středního věku $7 D008875
650    _2
$a celosvětové zdraví $7 D014943
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Gardner, Roy S $u Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Clydebank, UK
700    1_
$a Gras, Daniel $u L'Hopital Prive du Confluent, Nantes, France
700    1_
$a D'Onofrio, Antonio $u AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy
700    1_
$a Mark, George $u Cardiology Associates of the Delaware Valley, Haddon Heights, New Jersey, USA
700    1_
$a Nair, Devi $u Arrythmia Research Group, Jonesboro, Arkansas, USA
700    1_
$a Lellouche, Nicolas $u APHP, Paris, France
700    1_
$a Novak, Miroslav $u Faculty Hospital U sv Anny, Brno, Czechia
700    1_
$a Lo, Ronald $u VA Loma Linda, Loma Linda, Loma Linda, California, USA
700    1_
$a Chew, Engwooi $u Belfast City Hospital Trust, Belfast, UK
700    1_
$a Wright, David $u Liverpool Heart and Chest Hospital, Liverpool, UK
700    1_
$a Kaplan, Andrew $u Cardiovascular Associates of Mesa, Mesa, Arizona, USA
700    1_
$a Bertini, Matteo $u Cardiovascular Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy
700    1_
$a Veraghtert, Sara $u Boston Scientific Corporation, St. Paul, Minnesota, USA
700    1_
$a Harbin, Michelle M $u Boston Scientific Corporation, St. Paul, Minnesota, USA
700    1_
$a Matznick, Elizabeth $u Boston Scientific Corporation, St. Paul, Minnesota, USA
700    1_
$a Yong, Patrick $u Boston Scientific Corporation, St. Paul, Minnesota, USA
700    1_
$a Stein, Kenneth M $u Boston Scientific Corporation, St. Paul, Minnesota, USA
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 12, č. 3 (2025), s. 1832-1847
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39722592 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091102 $b ABA008
999    __
$a ok $b bmc $g 2366435 $s 1252705
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 12 $c 3 $d 1832-1847 $e 20241226 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace